Tetra Bio-Pharma Inc.
TBPMQ
$0.00
$0.000.00%
OTC PK
| 08/31/2022 | 05/31/2022 | 02/28/2022 | 11/30/2021 | 08/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -53.05% | -43.06% | -53.74% | -94.38% | 98.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.22% | -52.64% | -83.02% | -58.21% | 26.55% |
| Operating Income | 45.22% | 52.64% | 83.02% | 58.21% | -26.55% |
| Income Before Tax | 41.61% | 53.92% | 80.47% | -331.64% | -15.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.61% | 53.92% | 80.47% | -331.64% | -15.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.61% | 53.92% | 80.47% | -173.29% | 4.90% |
| EBIT | 45.22% | 52.64% | 83.02% | 58.21% | -26.55% |
| EBITDA | 45.33% | 52.73% | 83.25% | 58.68% | -26.17% |
| EPS Basic | 44.35% | 59.54% | 86.40% | -92.28% | 33.53% |
| Normalized Basic EPS | 49.33% | 61.62% | 86.30% | 47.97% | 8.54% |
| EPS Diluted | 44.35% | 59.54% | 86.40% | -92.28% | 33.53% |
| Normalized Diluted EPS | 49.33% | 61.62% | 86.30% | 47.97% | 8.54% |
| Average Basic Shares Outstanding | 5.43% | 13.61% | 43.49% | 42.18% | 42.48% |
| Average Diluted Shares Outstanding | 5.43% | 13.61% | 43.49% | 42.18% | 42.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |